Zydus Signs a License Agreement with XOMA to Advance IL-2- Based Immuno-Oncology Therapy

 Zydus Signs a License Agreement with XOMA to Advance IL-2- Based Immuno-Oncology Therapy

Zydus Signs a License Agreement with XOMA to Advance IL-2- Based Immuno-Oncology Therapy

Shots:

  • Zydus to advance the new IO therapies through formal clinical studies and receives exclusive rights to develop and commercialize the therapy in India, Brazil, Mexico and other emerging markets
  • XOMA retains the rights for all other territories and receives royalties on the sales in the licensed territories. The collaboration will combine Zydus’ IL-2 with XOMA’s anti-IL-2 mAb
  • Zydus to develop new IO therapy through human POC while each company will receive pre-defined shares of future proceeds that may arise under the license agreement

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Zydus

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post